{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:00:15Z","timestamp":1760299215228},"reference-count":30,"publisher":"Baishideng Publishing Group Inc.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2004]]},"DOI":"10.3748\/wjg.v10.i5.649","type":"journal-article","created":{"date-parts":[[2015,9,18]],"date-time":"2015-09-18T11:09:48Z","timestamp":1442574588000},"page":"649","source":"Crossref","is-referenced-by-count":31,"title":["Salvage therapy for hepatocellular carcinoma with thalidomide"],"prefix":"10.3748","volume":"10","author":[{"given":"Tsang-En","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Lin SC, Shih SC, Kao CR, Chou SY. Transcatheter arterial embolization treatment in patients with hepatocellular carcinoma and risk of pulmonary metastasis. World J Gastroenterol 2003;9:1208-1211.","DOI":"10.3748\/wjg.v9.i6.1208"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/339058a0"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200006000-00023"},{"key":"ref4","unstructured":"Lin AY, Brophy N, Fisher GA, So S, Biggs C, Yock T, Levitt L. Phase II study of thalidomide in patients (pts) with unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2002;21:p97b abstr: 2202."},{"key":"ref5","unstructured":"Kong HL, Boyer MJ, Lim R, Clarke S, Milward JM, Wong E. Phase II trial of thalidomide in unresectable hepatocellular carcinoma (HCC)–a cancer therapeutics group (CTRG) study. Proc Am Soc Clin Oncol 2001;20:p133b, abstr: 2282."},{"key":"ref6","unstructured":"Patt YZ, Hassan MM, Lozano RD, Zeldis JB, Schnirer I, Frome A, Abbruzzese J, Wolff R, Brwom T, Lee E. Phase II trial of thalidomide for treatment of nonresectable hepa-tocellular carcinoma. Proc Am Soc Clin Oncol 2000;14:1035."},{"key":"ref7","unstructured":"Schwartz JD, Sung Max W, Lehrer D, Goldenberg A, Muggia F, Volm M. Thalidomide for unresectable hepatocellular cancer (HCC) with optional interferon-\\upon disease progression. Proc Am Soc Clin Oncol 2002;abstr:1847."},{"key":"ref8","unstructured":"Jacqueline WP, Chen LT. Thalidomide and hepatoma. NHRI-AACR Joint Conference 2001 abstr: 653. (The Fifth Taiwan Can-cer Clinical Research Organization Cooperative Annual Confer-ence and Cross-Strait Anti-Cancer Pharmaceuticals Research and Development Conference.) http: \/\/tpmd.nhri.org.tw\/~scba\/php-bin\/scba2001\/abstract\/abs653.htm. ."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1053\/he.2000.5628"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-10-199711150-00023"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00408-8"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.6.1675"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5935\/0305-7518.19850006"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.11.1885"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.9.2286-2290.2000"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(98)00046-X"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.4082"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s002800051104"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1998.18.1069"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.1.210"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.387"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1023\/A:1021919224972"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.35342"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E"},{"key":"ref25","unstructured":"Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD, Goldschmidt H. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002;8:3377-3382."},{"key":"ref26","unstructured":"Feun LG, Marini A, Molina E, O'Brien C, Schiff E, Jeffers L, Savaraj N. Thalidomide as palliative care for patients with unresectable hepatocellular carcinoma. Proc Am Soc Clin Oncol 2003;abstr:865."},{"key":"ref27","unstructured":"von Moos R, Stolz R, Cerny T, Gillessen S. Thalidomide: from tragedy to promise. Swiss Med Wkly 2003;133:77-87."},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Schwartz JD, Sung M, Schwartz M, Lehrer D, Mandeli J, Liebes L, Goldenberg A, Volm M. Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist 2005;10:718-727.","DOI":"10.1634\/theoncologist.10-9-718"},{"key":"ref29","unstructured":"Chun HG, Waheed F, Iqbal A, Wolf DC, Li Z, Kempin SJ. A com-bination of capecitabine and thalidomide in patients with unresectable, recurrent or metastatic hepatocellular carcinoma. Proc Am Soc Clin Oncol 2003;Abstr:1407."},{"key":"ref30","unstructured":"Chen CS, Hillebrand D, Hill K, Lilly M. A pilot study of celecoxib combined with escalating doses of thalidomide for treatment of unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2002;abstr:2350."}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v10\/i5\/649.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T18:24:53Z","timestamp":1567189493000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v10\/i5\/649.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.v10.i5.649","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2004]]}}}